Testing rates for mismatch repair and microsatellite instability among patients with CRC increased from 2012 to 2021, but variations by cancer stage and other factors still exist.
increased from 22.7% in 2012 to 71.5% in 2021, but variations in access remain, with testing rates differing by cancer stage, individual hospital, patient sex, race, and insurance status.In 2017, the National Comprehensive Cancer Network recommended universal testing for MMR and MSI among patients with CRC, but studies suggest that testing may still be underused.
About 22% variability in MMR/MSI testing was attributed to hospital-level variations, with the best vs worst performing hospitals reporting testing rates of 90% vs 2%. This hospital-level variation may be due to testing protocol differences at individual institutions, the authors said.
Colorectal Cancer (CRC) Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Practice Management Revenue Colon Cancer Malignant Neoplasm Of The Colon Malignant Neoplasm Of The Large Intestine Malignant Rectal Neoplasm Rectal Cancer Cancer Of The Rectum Rectal Carcinoma Hospitals Microsatellite Instability MSI Insurance Adherence
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Adjuvant Aspirin Trial in CRC InconclusiveInvestigators compared outcomes between patients with stage II/III colon cancer given adjuvant aspirin and those given placebo.
Read more »
Fecal Immunochemical Test Performance for CRC Screening Varies WidelyCommonly used fecal immunochemical tests vary in their performance, which has implications for the benefits and cost-effectiveness of FIT-based CRC screening programs.
Read more »
High-Dose Vitamin D Disappoints in Metastatic CRC: SOLARISHigh-dose vitamin D added to chemotherapy failed to provide a benefit in patients with metastatic colorectal cancer in the SOLARIS trial.
Read more »
CRC Screening After 75: Is Shared Decision-Making Helpful?Training physicians in shared decision-making did not significantly improve the rate of older adults receiving their preferred approach to colorectal cancer screening in a randomized controlled trial.
Read more »
FDA OKs Next-Gen Cologuard Test for CRC ScreeningIn average-risk adults, Cologuard Plus demonstrated sensitivities of 95% for CRC and 43% for advanced precancerous lesions at 94% specificity in the pivotal BLUE-C trial.
Read more »
General Mills edges lower premarket; US Steel climbsGeneral Mills edges lower premarket; US Steel climbs
Read more »